Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California

Abstract

skinny labeling, our findings suggest that generic drug entry for susceptible brand-name drugs could be delayed by multiple years. A limitation of the study is that our strict criteria for determining susceptibility to skinny labeling may have underestimated the delay.Despite the practice of skinny labeling being explicitly permitted by statute, recent court decisions have increased the financial risk of generic manufacturers considering using a skinny label by subjecting them to claims for inducement of patent infringement. 5 Subjecting generic manufacturers to heightened risk of legal damages for their skinny labels could reduce incentives to use this pathway and lead to delays in generic competition that lowers prices for patients and the health care system.The US Congress and the FDA could consider actions to ensure that skinny labeling remains an attractive pathway for generic manufacturers. Skinny labels prevent brand-name drug manufacturers from delaying competition by obtaining patents covering subsequent FDA-approved indications of their drugs.

Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

“…Some studies suggest that patients with COVID-19 have a relatively low rate of post-discharge VTE(29)(30)(31)(32). Further, a recent study did not identify a significantly increased risk of post-discharge VTE in patients with SARS-CoV-2 infection compared with non-infected individuals (33). The current study did not include a 'no anticoagulation' group upon hospital discharge.…”

SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia

“…Despite systematic thromboprophylaxis during hospitalization of patients with COVID-19, the incidence of thrombosis ranges from 7 to 8% in traditional hospitalization to 25 to 30% in intensive care. [27][28][29] We must also take into account the potential sequelae described in so-called "long COVID" after the hospitalization. 30 All these data highlight that during infection with SARS-CoV-2 and its related disease (COVID- 19), thrombosis occurs at least 100-fold more often without vaccination than after it.…”

“…Despite systematic thromboprophylaxis during hospitalization of patients with COVID-19, the incidence of thrombosis ranges from 7 to 8% in traditional hospitalization to 25 to 30% in intensive care. 27 28 29 We must also take into account the potential sequelae described in so-called “long COVID” after the hospitalization. 30…”

The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper

“…Despite systematic pharmacological thromboprophylaxis in patients hospitalized with COVID-19 at the conventional ward or ICU, the incidence of thrombosis ranges from 7–8% to 25–30% respectively. 64 65 66 In Western countries, the actual mortality rate in patients with COVID-19 admitted to the ICUs is up to 30%, whereas the morbidity of long COVID-19 complications is not negligible. 67 68 Nevertheless, this situation might negatively affect the psychological adherence of the population at the vaccination program and raise some concerns leading to enhanced pharmacovigilance.…”